Literature DB >> 7989936

Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.

M D Tabone1, C Kalifa, C Rodary, M Raquin, D Valteau-Couanet, J Lemerle.   

Abstract

PURPOSE AND METHODS: Between January 1981 and June 1993, 137 children and adolescents were each treated at the Institut Gustave Roussy for an initially nonmetastatic osteosarcoma of the extremities. We report the retrospective analysis of 42 cases of recurrence that occurred in this population.
RESULTS: The median interval between the diagnosis of the primary osteosarcoma and the first recurrence was 21 months (range, 5 to 60). The site of the first recurrence was limited to the lung in 20 patients, the bone in seven patients, was local in six patients, and was confined to soft tissue in one patient. In eight patients, the first recurrence affected multiple sites. Subsequent recurrences often involved unusual or multiple sites. Management of recurrences included surgery and/or various regimens of second-line chemotherapy, and in one case involved high-dose chemotherapy followed by autologous bone marrow transplantation. Overall survival and event-free survival were, respectively, 36% and 27% at 36 months. At present, 13 patients are alive without evidence of disease. Response of the primary tumor to preoperative chemotherapy, the time between the diagnosis and the first recurrence, and the number of metastatic lesions did not correlate with survival. The survival rate is better in patients with a local or a pulmonary first recurrence.
CONCLUSION: The most important prognostic indicator at first recurrence seems to be the possible complete resection of disease. Patients not amenable to surgery and patients with a second or a third recurrence have a poor prognosis. The potential benefit of more aggressive treatments such as high-dose chemotherapy and autologous bone marrow transplantation should be investigated for these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989936     DOI: 10.1200/JCO.1994.12.12.2614

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.

Authors:  Aina He; Weixiang Qi; Yujing Huang; Yuanjue Sun; Zan Shen; Hui Zhao; Yumei Yang; Yang Yao
Journal:  Int J Clin Oncol       Date:  2012-04-26       Impact factor: 3.402

2.  Unusual abdominal metastases in osteosarcoma.

Authors:  Simon Berhe; Enrico Danzer; Paul Meyers; Gerald Behr; Michael P LaQuaglia; Anita P Price
Journal:  J Pediatr Surg Case Rep       Date:  2018-01

Review 3.  Stratifying osteosarcoma: minimizing and maximizing therapy.

Authors:  Lisa M Niswander; Su Young Kim
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

4.  Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7.

Authors:  Yongzheng Bao; Bin Chen; Qiang Wu; Konghe Hu; Xinhua Xi; Wengang Zhu; Xueren Zhong; Jianting Chen
Journal:  Clin Exp Med       Date:  2015-10-29       Impact factor: 3.984

5.  Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.

Authors:  Carola A S Arndt; Nadya V Koshkina; Carrie Y Inwards; Douglas S Hawkins; Mark D Krailo; Doojduen Villaluna; Peter M Anderson; Allen M Goorin; Martin L Blakely; Mark Bernstein; Sharon A Bell; Kaylee Ray; Darryl C Grendahl; Neyssa Marina; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2010-06-24       Impact factor: 12.531

6.  Patients with osteosarcoma with a single pulmonary nodule on computed tomography: a single-institution experience.

Authors:  Israel Fernandez-Pineda; Najat C Daw; Beth McCarville; Liza J Emanus; Bhaskar N Rao; Andrew M Davidoff; Stephen J Shochat
Journal:  J Pediatr Surg       Date:  2012-06       Impact factor: 2.545

7.  Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.

Authors:  Sarah E S Leary; Amy W Wozniak; Catherine A Billups; Jianrong Wu; Valerie McPherson; Michael D Neel; Bhaskar N Rao; Najat C Daw
Journal:  Cancer       Date:  2013-04-26       Impact factor: 6.860

8.  What are the factors that affect survival and relapse after local recurrence of osteosarcoma?

Authors:  Akihiko Takeuchi; Valerae O Lewis; Robert L Satcher; Bryan S Moon; Patrick P Lin
Journal:  Clin Orthop Relat Res       Date:  2014-07-01       Impact factor: 4.176

9.  Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.

Authors:  Serena S Freeman; Steven W Allen; Ramapriya Ganti; Jianrong Wu; Jing Ma; Xiaoping Su; Geoff Neale; Jeffrey S Dome; Najat C Daw; Joseph D Khoury
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

Review 10.  Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.

Authors:  Akio Sakamoto; Yukihide Iwamoto
Journal:  Rev Recent Clin Trials       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.